Calidi Biotherapeutics Director James Schoeneck Receives Options

What Happened James A. Schoeneck, a director of Calidi Biotherapeutics (CLDI), was granted non‑qualified stock options to purchase 5,000 shares on August 17, 2026. The options carry an exercise price of $1.36 per share (the closing price on the grant date) and were recorded as a derivative award with no cash paid at grant. Because the exercise price equals the market price at grant, the options had no immediate intrinsic value.

Key Details

• Transaction type: Award/Grant of stock options (Derivative, code A)
• Grant date / Reported period: August 17, 2026; Form 4 filed August 19, 2026 (appears timely)
• Options: 5,000 shares; exercise price $1.36 per share (total underlying market value at grant ≈ $6,800)
• Vesting: 1/12th of the options vest per month over one year beginning on the grant date (fully vest after 12 months)
• Plan and policy: Granted under the issuer’s 2023 Equity Incentive Plan and the non‑employee director compensation policy
• Footnote: Filing notes this grant does not include previously granted options to the reporting person
• Shares/ownership after transaction: Not disclosed in the Form 4 provided

Context This was a derivative award (stock option grant), not an outright purchase of shares. Because the exercise price equals the market price at grant, the award did not provide immediate intrinsic gain; value to the director depends on future stock appreciation. Such director option grants are commonly part of non‑employee director compensation and are routine rather than a direct signal of buy/sell intent.